The effect of angiotensin (1-7) on bone marrow stem cells:adjunctive pharmacological therapy for cell transplantation in heart failure by Qian, Cheng
  
 University of Groningen
The effect of angiotensin (1-7) on bone marrow stem cells
Qian, Cheng
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2008
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Qian, C. (2008). The effect of angiotensin (1-7) on bone marrow stem cells: adjunctive pharmacological
therapy for cell transplantation in heart failure. s.n.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the














Introduction and aim of the thesis 
CHAPTER 1 
 10 
Current therapeutic approaches to chronic heart failure (CHF) entail pharmacological 
reductions in oxygen demand in tissue with insufficient vascular supply or interventional 
restoration of blood flow. Pharmacologically induced reductions in energy needs or 
ventricular remodeling, although potentially beneficial for cardiac function,  have hardly 
affected prognosis, as mortality rate in patients with CHF has remained stable over the last 5 
years [1]. In addition, mechanical revascularization carries the risk of restenosis. Alternate 
therapeutic approaches would therefore be desirable in patients with CHF. Accordingly, 
investigations have focused on the development of “stem-cell based regenerative medicine” as 
potential alternative. 
 
1.1 Chronic heart failure  
Chronic heart failure (CHF) is clinical syndrome which may develop as a consequence of 
both peripheral and cardiac disorders characterized by various clinical signs and symptoms. 
CHF is a progressive disorder of neurohormonal activation and left ventricular remodeling. 
After acute myocardial infarction, all structural alterations in cardiac architecture, at organ as 
well as at tissue and cellular level, are referred to as myocardial remodeling. Post-infarction 
remodeling has been divided into two phases: early compensatory phase and late 
decompensate phase [2,3]. During the remodeling process three major components of the 
myocardium are involved in: myocytes, extracellular matrix and blood vessels. In the early 
phase irreversibly damaged tissue is replaced by scar tissue: in the infarcted area, myocyte 
necrosis and acute permeable inflammation at the border of the necrotic myocytes occurs, 
followed by inflammation, fibroblast and vascular cell proliferation, extracellular matrix 
deposition, as well as circulating or bone marrow stem cell recruitment. In the non-infarcted 
area, to compensate for the loss of contractile tissue, myocytes hypertrophy and interstitial 
fibrosis occur.  During the development of cardiac hypertrophy, a mismatch between the 
number of capillaries and the size of cardiomyocytes develops, leading to myocardial hypoxia 
[4,5]. The putative capability of angiogenic stem cell is to generate neovascularization via 
vasculogenesis. Hence, it has been postulated that therapeutic transplantation of bone marrow 
angiogenic stem cells may contribute to postinfarcted neovasculogenesis in the myocardial 
tissue, either by paracrine or regenerative mechanisms.  
 
1.2 Formation of blood vessel growth 
All blood vessels share a number of basic features, although detailed gene expression pattern, 
morphology, and function may vary between different vessel beds. The inside of blood 
vessels is lined with endothelium, consisting of a layer of endothelial cell, which separates 
blood from tissues. The outside of the endothelium is covered with a specialized layer of 
connective tissue followed by a layer of mural cells (pericytes and vascular smooth muscle 
cells) [6,7]. Vessel growth requires tip cells serving as pioneer guider and pericytes to 
stabilize the vessel. On Matrigel coated culture plates, in-vitro culture with bone marrow-
derived angiogenic cells mimics the in-vivo vessel growth (Figure 1). Neovascularization is a 
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tightly controlled process where endothelial/progenitor cell proliferation and migration are 
regulated by secreted factors as well as by surrounding cells and matrix [8].  
The vascular system mainly originates from two fundamental processes: vasculogenesis and 
angiogenesis. Vasculogenesis is the formation of a primary plexus of vessels by stem cells, so 
called hemangioblasts. During this procedure, endothelial precursors undergo differentiation 
to endothelial cell in combination with the formation of an in-situ vascular network and 
remodeling, whereas angiogenesis is defined as the sprouting of new capillaries or splicing 
from preexisting vessels [9,10]. It has long been accepted that vasculogenesis is limited to 
early embryo period but not in adulthood, while angiogenesis occurs in both embryonic and 
postnatal life. However, this paradigm has been changed now that both vessel formations are 
observed during embryonic and adult growth processes [11-13]. After ischemic injury, 
ischemia leads to expression of hypoxia inducible factor-1 alpha; stromal derived factor-1; 
and the pro-angiogenic factor-vascular endothelial growth factor, which initiates the 
procedure of neovascularization characterized by at least four steps; i.e. mobilization; 
permeability; proliferation and lumen stabilization [8,14].  
 
 



















1.3 Angiotensin-(1-7) and its pleiotropic actions 
The renin-angiotensin-system (RAS) is a cascade of enzymatic reactions resulting ultimately 
in the formation of angiotensin II. Recent research has expanded the knowledge about the 
RAS by adding new components to the pathways: angiotensin-(1-5), angiotensin-(1-7) [Ang-
(1-7)], angiotensin-(1-9), an angiotensin converting enzyme (ACE) homologous enzyme, 
Figure 1: Vascular tube formation on Martrigel: after cultured with EBM-2 medium for 7 days, bone marrow-derived 
endothelial progenitor cells were reseeded on Martrigel coated culture plates. Vascular tube formation was observed 
within 6 hours and can be further expanded after 24 hours culture. The vascular tube formation may be in network form or 
vascular tree-like structure (left). In this structure, tip cell served as pioneer cell (right upper) to open the avenue and guide 







ACE2, and the G-protein-coupled receptor Mas as a molecular receptor for Ang-(1-7) [15-
17]. Ang-(1-7) can be directly or indirectly converted from Ang I or Ang II by several 
enzymes (Figure 2). After cutting of the last amino acid-phenylalanine, Ang II is covert to 
Ang-(1-7) (Figure 3). As a counteractor of angiotensin II, it has become clear that Ang-(1-7) 
contributes to the cardiovascular effects of ACE inhibitors and AT1-receptor-blockers both in 








One of the major understandings of the role of Ang-(1-7) is related to cardiac effects via Mas 
receptors. In a rat myocardial infarction model, chronic intravenous infusion of Ang-(1-7) 
markedly attenuated heart failure and reduced myocardial infarction [20].  An important 
aspect related to the cardioprotection produced by the Ang-(1-7)-Mas  axis lies on its 
independent role on blood pressure [21-23]. In addition to its effects on cardiac remodelling, 
Ang-(1-7) possesses anti-arrythmic effects, which may be due to changes in sodium pump 
activity [24]. Moreover, Ang-(1-7) mediated by Mas receptors, appears to be involved in 
antiproliferation of vascular smooth muscle cell, fribroblast and in-stent induced neointima 
formation [25-27].  
 AT1 





Angiotensin I (1-10) 




ACE2, PEP, PCP 
Effects:      Vasoconstriction  
                  Edothelial dysfunction 
                  Hypertrophy 
                  Fibrosis 
                  Atherosclerosis  
                  Arrhythmogenesis 








Figure 2: The formation of Angiotensin-(1-7) and its counteractor effects against Angiotensin II in cardiovascular system. 
The number between brackets indicates the composition of acid amino peptides. In the RAS, Ang-(1-7) can be directly 
converted from Ang I via endopeptidases or from Ang II via angiotensin converse enzyme-2 (ACE2), prolylendopeptidase 
(PEP) and prolylcarboxypeptidase (PCP). Furthermore, ACE2 can also form Ang-(1-9), from which Ang-(1-7) can be 
converted via ACE and neutral endopeptidase (NEP). 
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It is well documented that the vasodilatory activity of Ang-(1-7) is endothelium dependent 
[28]. By binding to endothelial cells Ang-(1-7) can stimulate the production of nitric oxide, 
prostaglandins or endothelium-derived relaxing factor [29]. Importantly, Ang-(1-7) induces 
the release of nitric oxide through coordinated phosphorylation or dephosphorylation of 
endothelial nitric oxide synthase. This effect involved an upstream mechanism; the activation 
of the phosphatidylinositol 3-kinase (PI3k)-Akt pathway [30], which may play a crucial role 
in differentiation of bone marrow-derived stem cells. Recently, an increasing body of 
evidence from Rodgers’s group showed that Ang-(1-7) administration significantly improved 
bone marrow recovery after radiochemotherapy in cancer patients [31-34], supporting a role 
for Ang-(1-7) in bone marrow cell related processes. The effects of Ang-(1-7) on bone 
marrow derived endothelial progenitor cells will be studied in the present thesis 
 
1.4 The aim of this thesis 
In the last decade, stem cell therapy displayed a promising strategy for the treatment of CHF. 
Transplantation of angiogenic bone marrow-derived endothelial progenitor cells (BM-EPCs), 
however, generated inconsistent results both in animal experiments and clinical trials. 
Moreover, the functional activity of EPCs is impaired in patients with CHF [35,36], which 
may negatively influence therapeutic potential of autologous bone marrow cells. Early 
pharmacological intervention may salvage the damaged heart and improve the function of 
autologous bone marrow stem cells. Therefore, the aim of this thesis was to investigate 
whether pharmacological pretreatment of BM-EPCs with Ang-(1-7) may enhance therapeutic 
angiogenesis in the failing heart. The relevant experiments for this investigation were 
conducted in three steps: 
1. The effects of Ang-(1-7) on bone marrow-derived progenitors were extensively evaluated 
both in vitro and in vivo. 
2. A promising technique was set up to homogenously transplant bone marrow-derived 
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3. Therapeutic potential of bone marrow-derived progenitors was evaluated in a rat 
myocardial infarction model.  
The effect of Ang-(1-7) on bone marrow progenitors, including hematopoietic and angiogenic 
progenitors, was comprehensively addressed in Chapter 2. In Chapter 3, a technique was 
established to transplant BM-EPCs into rat heart via intracoronary delivery. Then, based on 
this technique, therapeutic potential of ex-vivo expanded bone marrow-derived angiogenic 
cells was evaluated in a rat myocardial infarction model (Chapter 4), also addressing the 
question whether in vitro pre-stimulation of bone marrow-derived angiogenic cells by Ang-(1-
7) could further enhance therapeutic potential of these cells. Chapter 5 presents a detailed 
review, describing the microenvironment of BM-EPCs in response to ischemia injury and 
physiological and pharmacological factors beneficial to BM-EPCs function, as well as future 
perspectives for cell based therapeutic angiogenesis. Finally, the results of these studies were 
discussed and summarized in Chapter 6.  
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